Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Seema A Bhat
Ohio State University Comprehensive Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Nci - Center for Cancer Research
Bethesda, Maryland, United States
Robert J. KreitmanRecruiting - Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Seema A. BhatRecruiting - University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
Robert L. RednerRecruiting - University of Virginia Cancer Center
Charlottesville, Virginia, United States
Nathan L. RobertsRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 May 2026
- Primary completion
- 1 Mar 2030
- Completion
- 1 Mar 2030
- Last update posted
- 3 Jun 2026
- Registered enrollment
- 84
- Registry id
- NCT06965114
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.